Pre-clinical studies using a range of murine tumor models have shown that intratumoral injection of ADU-S100 leads to induction of tumor-specific CD8+ T cells [69,70], and that addition of ADU-S100 to anti-PD1 or anti-PD1/anti-CTLA4 antibodies in combination therapies results in enhanced tumor-specific T cell responses and superior anti-tumor efficacy [71,72]. Here, CD8A is linked to neoplasm.